Impaired PBPC collection in patients with myeloma after high-dose melphalan

By Jansen J   Thompson JM   Dugan MJ   Wiemann MC   Hanks S   Greenspan AR   Akard LP  

Cytotherapy, Vol. 6, Iss. 5, 2004-10 ,pp. : 498-504

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma

By Guardino Ae   Rajapaksa R   Ong Kh   Sheehan K   Levy R  

Cytotherapy, Vol. 8, Iss. 3, 2006-05 ,pp. : 277-289

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Predictors of high yield and purify of CD34⁺ cell-selected PBPC, collected from patients with multipe myeloma

By Webb I J   Scholssman R L   Jiroutek M   Doss D   Cohen C A   Freeman A   Schott D M   Anderson K C  

Cytotherapy, Vol. 1, Iss. 3, 1999-01 ,pp. : 175-182

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood

By Louis SA   Zapf R   Clarke E   Thomas TE   Sutherland HJ  

Cytotherapy, Vol. 3, Iss. 6, 2001-11 ,pp. : 489-504

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor

By Taubert Isabel   Saffrich Rainer   Zepeda-Moreno Abraham   Hellwig Isabelle   Eckstein Volker   Bruckner Thomas   Ho Anthony D.   Wuchter Patrick  

Cytotherapy, Vol. 13, Iss. 4, 2011-04 ,pp. : 459-466

Ashgate Publishing Ltd

Access to resources Recommend Favorite